The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Amitriptyline v.the rest: still the leading antidepressant after 40 years of randomised controlled trials
Open accessAbstract
Background: Tricyclic antidepressants have similar efficacy and slightly lower tolerability than selective serotonin reuptake inhibitors (SSRIs). However, there are no systematic reviews assessing amitriptyline, the reference tricyclic drug,v.other tricyclics and SSRIs directly. Aims: To review the tolerability and efficacy of amitriptyline in the management of depression. Method: A systematic review of randomised controlled trials (RCTs) comparing amitriptyline with other tricyclics/heterocyclics or with an SSRI. Results: We reviewed 186 RCTs. The overall estimate of the efficacy of amitriptyline revealed a standardised mean difference of 0.147 (95% CI 0.05–0.243), significantly favouring amitriptyline. The overall OR for dropping out was 0.99 (95% CI 0.91–1.08) and that for side-effects was 0.62 (95% CI 0.54–0.70), favouring the control drugs. With drop-outs included as treatment failures, the estimate of the effectiveness of amitriptyline v.tricyclics/heterocyclics and SSRIs showed a 2.5% difference in the proportion of responders in favour of amitriptyline (number needed to treat 40, CI 21–694; OR 1.12 (95%CI 1.01–1.24)). Conclusions: Amitriptyline is less well tolerated than tricyclics/heterocyclics and SSRIs, but slightly more patients treated on it recover than on alternative antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
Song, F., Freemantle, N., Sheldon, T. A., House, A., Watson, P., Long, A., & Mason, J. (1993) · BMJ · doi:10.1136/bmj.306.6879.683 · Cited by 399
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Recurrence of depression after discontinuation of long-term amitriptyline treatment
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.3.325 · Cited by 62
Blacker, R., Shanks, N. J., Chapman, N., & Davey, A. (1988) · Psychopharmacology · doi:10.1007/bf00172625 · Cited by 39
Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline.
Montgomery, S., Cronholm, B., Asberg, M., & Montgomery, D. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb04580.x · Cited by 28
Marchesi, C., Ceccherininelli, A., Rossi, A., & Maggini, C. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979331 · Cited by 24
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“However, other studies comparing TCAs and SSRIs in patients with depression have shown that TCAs, such as amitriptyline, have superior efficacy (Barbui and Hotopf, 2001; Faravelli et al., 2003).”
ResultMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 538
Meta-analytical studies on new antidepressants
Anderson, I. M. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.161 · Cited by 351
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Guaiana, G., Barbui, C., & Hotopf, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004186.pub2 · Cited by 271
Self-citationEmpirical evaluation of the assumptions in identifying evidence based treatments in mental health
Blatt, S. J., & Zuroff, D. C. (2005) · Clinical Psychology Review · doi:10.1016/j.cpr.2005.03.001 · Cited by 199
Antidepressants for the treatment of depression in people with cancer
Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C., & Hotopf, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub3 · Cited by 158
Self-citationResidual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Increase in Antidepressant Medication in the US Adult Population between 1990 and 2003
Mojtabai, R. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112885 · Cited by 100
Stenkrona, P., Halldin, C., & Lundberg, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.002 · Cited by 78
Antidepressants for the treatment of depression in people with cancer
Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub4 · Cited by 73
Self-citationPharmacotherapy to sustain the fully remitted state
Kennedy, S., McIntyre, R., Fallu, A., & Lam, R. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0245 · Cited by 56
Kirwin, J. L., & Gören, J. L. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.3.396.61600 · Cited by 42
Metadata
- Authors
- Barbui, C., & Hotopf, M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2001-02
- Volume
- 178
- Issue
- 2
- Pages
- 129-144
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2092718449
- Cited by
- 182
- References
- 11
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.